Savara Inc. (SVRA)
| Market Cap | 1.25B +49.1% |
| Revenue (ttm) | n/a |
| Net Income | -152.74M |
| EPS | -0.61 |
| Shares Out | 269.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,231,765 |
| Open | 4.800 |
| Previous Close | 4.720 |
| Day's Range | 4.580 - 4.845 |
| 52-Week Range | 4.030 - 7.005 |
| Beta | 0.30 |
| Analysts | Strong Buy |
| Price Target | 11.06 (+138.36%) |
| Earnings Date | Nov 10, 2026 |
About SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for SVRA stock is "Strong Buy." The 12-month stock price target is $11.06, which is an increase of 138.36% from the latest price.
News
Savara Announces New Employment Inducement Grant
YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employ...
Savara assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of Savara (SVRA) with a Buy rating and $10 price target The firm likes the company’s path to becoming the first approved therapy in autoimmune pulmonary…
Savara Quarterly report: Q3 2026
Savara has published its Q3 2026 quarterly earnings report on November 9, 2026.
Savara Slides: Corporate presentation
Savara has posted slides in relation to its latest quarterly earnings report, which was published on November 9, 2026.
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the CHEST 2026 Annual Me...
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an encore oral presentatio...
Savara Slides: Corporate presentation
Savara has posted slides in relation to its latest quarterly earnings report, which was published on October 8, 2026.
Savara initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Savara (SVRA) with an Overweight rating and $12 price target The firm sees “plenty of catalysts” for Savara in the near-term, including the potential approval of…
Savara announces presentations of Results from Phase 3 trial of Molgramostim
Savara (SVRA) announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September…
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two po...
Savara reports Q2 EPS (16c), consensus (15c)
“While we have regulatory applications under review across the U.S., EU, and U.K., the U.S. represents our nearest-term opportunity,” said Matt Pauls, J.D., M.B.A., Chair and Chief Executive Officer, ...
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second qu...
Savara Quarterly report: Q2 2026
Savara has published its Q2 2026 quarterly earnings report on August 11, 2026.
Savara Earnings release: Q2 2026
Savara released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Savara Slides: Corporate presentation
Savara has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Savara announces EPO granted a patent covering formulation of Molbreevi
Savara (SVRA) announced that the European Patent Office, EPO, has granted a patent covering the liquid formulation of Molbreevi, an orally inhaled recombinant human granulocyte-macrophage colony-stimu...
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Off...
Savara Slides: Corporate presentation
Savara has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
Palvella Therapeutics appoints Savara CEO Matt Pauls to board
Palvella Therapeutics (PVLA) announced the appointment of Matt Pauls to its board of directors. Since 2020, he has served as chair of the board of directors and CEO of Savara…
Savara says CFO Dave Lowrance stepping down for health reasons
Savara (SVRA) “announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition,...
Savara Announces Chief Financial and Administrative Officer Transition
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Fi...
Savara Transcript: AGM 2026
The meeting covered director elections, amendments to the certificate of incorporation and incentive plan, auditor ratification, and executive compensation. All proposals passed, and a Q&A session followed for stockholders.
Savara Transcript: Jefferies Global Healthcare Conference 2026
MOLBREEVI, an inhaled biologic for autoimmune PAP, is under FDA review with a PDUFA date in November and strong confidence in approval. The US market is estimated at 5,500 patients, with pricing set at $400,000–$500,000 per year and a robust launch plan in place. High retention and safety in trials support broad use, including in mild cases.
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the manage...
Savara presents poster at ATS 2026 International Conference on IMPALA-2
Savara (SVRA) presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind…